If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

HCWB Insider Trading (HCW Biologics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 44.00%

Insider Buying (Last 12 Months): $62,126.68

Insider Selling (Last 12 Months): $0.00

HCW Biologics Insider Trading History Chart

HCW Biologics Share Price & Price History

^$2.26

▲ +0.03 (1.35%)

As of 08/16/2022 01:00 AM ET

Days: 30 | 90 | 365

A One Stop Shop for Everything Futures Trading

From RJO Futures | Ad

Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!

Download your FREE Technical Analysis Trading Guide Today.

HCW Biologics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/13/2022	Rebecca Byam	CFO	Buy	7,596	$2.08	$15,799.68	96,596
6/10/2022	Gary M Winer	Director	Buy	1,500	$2.13	$3,195.00	13,000
6/9/2022	Hing C Wong	CEO	Buy	2,000	$2.25	$4,500.00	15,284,948
6/8/2022	Gary M Winer	Director	Buy	1,000	$2.27	$2,270.00	10,500
6/6/2022	Gary M Winer	Director	Buy	1,000	$2.13	$2,130.00	8,500
6/2/2022	Rick S Greene	Director	Buy	4,800	$2.09	$10,032.00	8,411
12/6/2021	Jin-An Jiao	VP	Buy	10,000	$2.42	$24,200.00

A One Stop Shop for Everything Futures Trading

From RJO Futures | Ad

Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for HCW Biologics (NASDAQ:HCWB)

1.03% of HCW Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HCW Biologics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/12/2022	BlackRock Inc.	39,583	$0.11M	0.0%	+136.8%	0.111%
5/12/2022	HighTower Advisors LLC	215,598	$0.59M	0.0%	+2,056.0%	0.602%
11/15/2021	HighTower Advisors LLC	14,000	$45K	0.0%	N/A	0.039%

Data available starting January 2016

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Today's Range

Now: $2.26

$2.25

$2.32

50 Day Range

MA: $2.28

$1.97

$2.67

52 Week Range

Now: $2.26

$1.76

$7.05

Volume

9,406 shs

Average Volume

9,381 shs

Market Capitalization

$80.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of HCW Biologics?: HCW Biologics' top insider investors include:
Hing C Wong (CEO)
Rebecca Byam (CFO)
Gary M Winer (Director)
Rick S Greene (Director)
Jin-An Jiao (VP)
Learn More about top insider investors at HCW Biologics.